Last reviewed · How we verify

CLE — Competitive Intelligence Brief

CLE (CLE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine replacement therapy / Levodopa combination. Area: Neurology.

marketed Dopamine replacement therapy / Levodopa combination Dopamine pathway; decarboxylase inhibition Neurology Small molecule Live · refreshed every 30 min

Target snapshot

CLE (CLE) — Impax Laboratories, LLC. CLE is a combination formulation of carbidopa and levodopa in an extended-release delivery system designed to provide more consistent dopamine replacement in the brain for Parkinson's disease management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CLE TARGET CLE Impax Laboratories, LLC marketed Dopamine replacement therapy / Levodopa combination Dopamine pathway; decarboxylase inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine replacement therapy / Levodopa combination class)

  1. Impax Laboratories, LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CLE — Competitive Intelligence Brief. https://druglandscape.com/ci/cle. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: